Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HUVR-CARTemis-1
- Development stage
- Unknown
- Lead developer
- Fundación Pública Andaluza para la Gestión de la Investigación
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
HUVR-CARTemis-1 is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by the Hospital Universitario Virgen del Rocío (HUVR) in collaboration with the Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI). This academic CAR-T product is engineered to target the B-cell maturation antigen (BCMA), a protein predominantly expressed on the surface of malignant plasma cells in multiple myeloma. The manufacturing process involves the genetic modification of a patient's own T lymphocytes using a lentiviral vector to express a CAR construct specific for BCMA. Once re-infused into the patient, these modified T cells recognize and eliminate BCMA-expressing tumor cells. HUVR-CARTemis-1 is currently being investigated in early-phase clinical trials for patients with relapsed or refractory multiple myeloma who have exhausted standard treatment options.
- Other names
- CARTemis-1CARTemis1CARTemis 1
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on HUVR-CARTemis-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HUVR-CARTemis-1.